Market Closed -
Swiss Exchange
09:00:41 29/04/2024 pm IST
|
5-day change
|
1st Jan Change
|
0.051
CHF
|
-13.56%
|
|
-11.46%
|
+24.39%
|
Fiscal Period: December |
2022
|
---|
Capitalization
1 |
19.96
|
Enterprise Value (EV)
1 |
24.2
|
P/E ratio
|
-1.07
x
|
Yield
|
-
|
Capitalization / Revenue
|
13.5
x
|
EV / Revenue
|
16.4
x
|
EV / EBITDA
|
-13,45,034
x
|
EV / FCF
|
-2.85
x
|
FCF Yield
|
-35.1%
|
Price to Book
|
1.03
x
|
Nbr of stocks (in thousands)
|
48,688
|
Reference price
2 |
0.4100
|
Announcement Date
|
30/05/23
|
Fiscal Period: December |
2020
|
2021
|
2022
|
---|
Net sales
1 |
0.0523
|
0.000331
|
1.475
|
EBITDA
|
-
|
-
|
-17.99
|
EBIT
1 |
-1.225
|
-4.248
|
-18.67
|
Operating Margin
|
-2,339.86%
|
-12,83,351.66%
|
-1,265.41%
|
Earnings before Tax (EBT)
1 |
-1.851
|
-11.86
|
-18.55
|
Net income
1 |
-1.851
|
-11.86
|
-18.55
|
Net margin
|
-3,537.48%
|
-35,83,562.54%
|
-1,257.72%
|
EPS
2 |
-0.1434
|
-0.8200
|
-0.3849
|
Free Cash Flow
1 |
-0.9785
|
0.6237
|
-8.489
|
FCF margin
|
-1,869.72%
|
1,88,432.33%
|
-575.47%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
Announcement Date
|
29/03/22
|
29/03/22
|
30/05/23
|
Fiscal Period: December |
2020
|
2021
|
2022
|
---|
Net Debt
1 |
9.07
|
-
|
4.23
|
Net Cash position
1 |
-
|
6.23
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-0.2354
x
|
Free Cash Flow
1 |
-0.98
|
0.62
|
-8.49
|
ROE (net income / shareholders' equity)
|
17.1%
|
-125%
|
-74.8%
|
ROA (Net income/ Total Assets)
|
-183%
|
-10.6%
|
-29.2%
|
Assets
1 |
1.013
|
112.2
|
63.55
|
Book Value Per Share
2 |
-1.720
|
0.6300
|
0.4000
|
Cash Flow per Share
2 |
0.0400
|
0.3000
|
0.0400
|
Capex
|
-
|
-
|
0.02
|
Capex / Sales
|
-
|
-
|
1.15%
|
Announcement Date
|
29/03/22
|
29/03/22
|
30/05/23
|
|
1st Jan change
|
Capi.
|
---|
| +24.39% | 4.36M | | -4.06% | 86.13B | | +1.97% | 39.82B | | +56.59% | 25.23B | | -14.82% | 15.36B | | -8.82% | 11.95B | | -16.29% | 11.6B | | -41.58% | 11.51B | | +6.14% | 8.71B | | -7.02% | 8.12B |
Biopharmaceuticals
|